Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

2.

For elderly, unfit patients, the all-oral AML regimen shows promise.

3.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

4.

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

5.

The risk of cancer is decreased by following international health recommendations.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot